Patents by Inventor Huiying Zhi

Huiying Zhi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220211017
    Abstract: A transgenic mouse comprising T30A, S32P, Q33L, N39D, and M470Q mutations in GPIIIa, as well as methods for making the transgenic mouse and methods for using the transgenic mouse to screen test compounds are described.
    Type: Application
    Filed: February 9, 2022
    Publication date: July 7, 2022
    Inventors: Peter J. Newman, Huiying Zhi
  • Patent number: 11266129
    Abstract: A transgenic mouse comprising T30A, S32P, Q33L, N39D, and M470Q mutations in GPIIIa, as well as methods for making the transgenic mouse and methods for using the transgenic mouse to screen test compounds are described.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 8, 2022
    Inventors: Peter J. Newman, Huiying Zhi
  • Publication number: 20210127648
    Abstract: A transgenic mouse comprising T30A, S32P, Q33L, N39D, and M470Q mutations in GPIIIa, as well as methods for making the transgenic mouse and methods for using the transgenic mouse to screen test compounds are described.
    Type: Application
    Filed: November 5, 2019
    Publication date: May 6, 2021
    Inventors: Peter J. Newman, Huiying Zhi
  • Publication number: 20200332259
    Abstract: A method of creating cells expressing specific red blood cell antigens is disclosed. In one embodiment, the method comprises the steps of (a) combining one or more guide RNAs targeting within a red blood cell antigen target locus; (b) adding a repair template comprising a mutation in the target locus flanked by a homology arm on each side, wherein the template may additionally include a diagnostic restriction enzyme site at the target locus; (c) ligating the guide sequence of step (b) into a plasmid which also expresses a nuclease and, optionally, a selectable marker or a reporter gene; (d) transfecting pluripotent cells with the plasmid of step (c) in the presence of an HDR repair oligo; (e) cloning and testing the resulting reporter positive clones for expression of the antigen target of interest; and (f) culturing the resulting cells to expand their numbers or to create a differentiated cell type of interest.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 22, 2020
    Inventors: PETER JAY NEWMAN, Sridhar Rao, Nanyan Zhang, Huiying Zhi
  • Patent number: 10725041
    Abstract: Methods of creating cells expressing specific platelet alloantigens by combining gene editing techniques and cell culture differentiation or expansion techniques employing pluripotent cells, including the steps of transfecting pluripotent cells with a plasmid encoding one or more guide RNAs targeting within a platelet alloantigen target locus and a nuclease in the presence of an HDR repair oligo and culturing the resulting cells to expand their numbers or to create a differentiated cell type of interest.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: July 28, 2020
    Assignee: VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC.
    Inventors: Peter Jay Newman, Sridhar Rao, Nanyan Zhang, Huiying Zhi
  • Publication number: 20160139124
    Abstract: A method of creating cells expressing specific platelet alloantigens is disclosed. In one embodiment, the method comprises the steps of (a) combining one or more guide RNAs targeting within a platelet alloantigen target locus; (b) adding a repair template comprising a mutation in the target locus flanked by a homology arm on each side, wherein the template may additionally include a diagnostic restriction enzyme site at the target locus; (c) ligating the guide sequence of step (b) into a plasmid which also expresses a nuclease and, optionally, a selectable marker or a reporter gene; (d) transfecting pluripotent cells with the plasmid of step (c) in the presence of an HDR repair oligo; (e) cloning and testing the resulting reporter positive clones for expression of the alloantigen target of interest; and (f) culturing the resulting cells to expand their numbers or to create a differentiated cell type of interest.
    Type: Application
    Filed: November 3, 2015
    Publication date: May 19, 2016
    Inventors: Peter Jay Newman, Sridhar Rao, Nanyan Zhang, Huiying Zhi